首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolu
admin
2013-11-29
87
问题
Without fanfare or legislation, the government is orchestrating a quiet revolution in how it regulates new medicines. The revolution is based on the idea that the sicker people are, the more freedom they should have to try drugs that are not yet fully tested. For fifty years government policy has been driven by another idea: the fear that insufficiently tested medicines could cause deaths and injuries. The urgent needs of people infected with HIV, the AIDS virus, and the possibility of meeting them with new drugs have created a compelling countervailing force to the continuing concern with safety. As a result, government rules and practices have begun to change. Each step is controversial. But the shift has already gone far beyond AIDS. New ways are emerging for very sick people to try some experimental drugs before they are marketed. People with the most serious forms of heart disease, cancer, emphysema, Alzheimer’ s or Parkinson’ s disease, multiple sclerosis, epilepsy, diabetes, or other grave illnesses can request such drugs through their doctors and are likelier to get them than they would have been four years ago. "We’ve been too rigid in not making lifesaving drugs available to people who otherwise face certain death," says Representative Henry Waxman, of California, who heads the subcommittee that considers changes in drug-approval policies. "It’s true of AIDS, but it’s also true of cancer and other life- threatening diseases."
For the first time, desperate patients have become a potent political force for making new medicines available quickly. People with AIDS and their advocates, younger and angrier than most heart-disease or cancer patients, are drawing on two decades of gay activists’ success in organizing to get what they want from politicians. At times they found themselves allied with Reagan Administration deregulators, scientists, industry representatives, FDA staff members, and sympathetic members of Congress. They organized their own clinical trials and searched out promising drugs here and abroad. The result is a familiar Washington story: a crisis—AIDS—helped crystallize an informal coalition for reform.
AIDS gave new power to old complaints. As early as the 1970s the drug industry and some independent authorities worried that the Food and Do, g Administration’ s testing requirements were so demanding that new drugs were being unreasonably delayed. Beginning in 1972, several studies indicated that the United States had lost its lead in marketing new medicines and that breakthrough drugs—those that show new promise in treating serious or life-threatening diseases— had come to be available much sooner in other countries. Two high-level commissions urged the early release of breakthrough drugs. So did the Carter Administration, but the legislation it pro- posed died in Congress. Complaints were compounded by growing concern that "if we didn’t streamline policies, red tape wot, Id be an obstacle to the development of the biotechnology revolution," as Frank E. Young, who was the head of the FDA from 1984 to 1989, put it in an interview with me.
Young was a key figure in the overhaul of the FDA’s policies. A pioneer in biotechnology and a former dean of the University of Rochester’s medical school, he came to Washington with an agenda and headed the agency for five and a half years—longer than anyone else has since the 1960s. Young took the FDA job to help introduce new medicines created by biotechnology-- whose promise he had seen in his own gene-cloning lab--and to get experimental medicines to desperately iii people more quickly. He had seen people die waiting for new medicines because "they were in the wrong place at the wrong time," he said. That is now changing.
From the second paragraph, we learn that ______.
选项
A、AIDS people tend to get angrier than all cancer patients
B、AIDS people have learned some experience from homosexual people in dealing with politicians
C、AIDS people have got some representatives in government organizations
D、AIDS people often work together with gay activists
答案
B
解析
转载请注明原文地址:https://kaotiyun.com/show/vHhO777K
0
考博英语
相关试题推荐
Thelawofprivateinternationaltribunalswithrespecttoconflictsofinterestofarbitratorsisquiteextensive,albeitbyno
Themarveloustelephoneandtelevisionnetworkthathasnowenmeshedthewholeworld,makingallmenneighbors,cannotbeextend
Justiceinsocietymustincludebothafairtrialtotheaccusedandtheselectionofanappropriatepunishmentforthoseproven
Variousinnovationshavebeenintroducedaswaystobreakoffoursystemwhichforcesstudentsthroughaseriesofidenticalcla
Youheartherefrainallthetime:theU.S.economylooksgoodstatistically,butitdoesn’tfedgood.Whydoesn’tever-greater
Governmenthastraditionallybeenevaluatedintermsoftheireffectsinpromotingseveralprinciples.Wehaveseenthatoneof
BetweentheinventionofagricultureandthecommercialrevolutionthatmarkedtheendoftheMiddleAges,wealthandtechnology
Justiceinsocietymustincludebothafairtrialtotheaccusedandtheselectionofanappropriatepunishmentforthoseproven
InTheDisunitingofAmerica:ReflectionsonaMulticulturalSociety,RevisedandEnlargedEdition(W.W.Norton)Schlesingerpr
TheInternetisaglobalnetworkthatconnectsothercomputernetworks,togetherwithsoftwareandprotocolsforcontrollingthe
随机试题
R12制冷剂与R134a制冷剂可使用同种型号的冷冻油。()
桡动脉穿刺置管的并发症有()
引起丹毒的最常见致病菌是
男孩,14岁。右髋部疼痛不适,活动后加剧,午后低热、盗汗、消瘦。以下不适合此患儿的病情治疗和护理项目是
推动人体生长发育及脏腑功能活动的气是
A.行气活血,通腑泻热B.通腑泻热,利湿解毒C.通腑泻热,解毒透脓D.通腑排脓,养阴清热E.温阳健脾,化毒排脓肠痈,症见右少腹疼痛,右下腹局限性压痛,轻度发热,恶心纳差,苔白腻。治宜
沟槽土方开挖到基底后,地基应由施工、监理、建设、勘察和设计等单位共同验收。对松软地基、坑洞等不符合要求的地基,应由()提出处理意见。
如果注册会计师采用以控制测试为主的方式进行存货监盘,并准备信赖被审计单位存货盘点的控制措施与程序,则其实施的绝大部分审计程序将限于()。
关于商鞅变法中的“改法为律”,下列说法错误的是
二分法查找仅限于这样的表;表中的数据元素必须有序,其存储结构必须是______。
最新回复
(
0
)